INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 20:35:54 05/06/2024 BST			5-day change	1st Jan Change
0.779 ^USD	-6.77%		-12.38%	-42.23%

05-15	INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Top Premarket Decliners	MT

INVO Bioscience, Inc. Announces Resignation of Jeffrey Segal as A Director

April 04, 2023 at 09:10 pm

INVO Bioscience, Inc. announced that on March 31, 2023, Jeffrey Segal MD submitted his resignation as a director of the Company. Dr. Segal's resignation was not because of any disagreements with the Company on matters relating to its operations, policies and practices.

Latest news about INVO Bioscience, Inc.

INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Top Premarket Decliners	04-18	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	04-17	MT
Top Midday Gainers	04-17	MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly	04-17	MT
Top Premarket Gainers	04-17	MT
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC	04-07	CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC	04-04	CI
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	02-08	CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	02-08	CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.	02-08	CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.	12-28	CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal	12-11	CI
Top Premarket Gainers	11-14	MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894	11-13	MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	11-10	MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call	31/10/23
Sector Update: Health Care Stocks Softer Late Afternoon	23/10/23	MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading	23/10/23	MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences	23/10/23	MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth	23/10/23	MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million.	22/10/23	CI
Transcript : INVO Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023	14/08/23

Chart INVO Bioscience, Inc.

Duration

Period

More charts

Company Profile

INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Companyâs flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the womanâs body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.

Sector

Medical Equipment, Supplies & Distribution

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
INVO BIOSCIENCE, INC.	-42.23%	3.18M
ABBOTT LABORATORIES	-6.18%	180B
MEDTRONIC PLC	-0.27%	109B
BECTON, DICKINSON AND COMPANY	-3.45%	68.93B
DEXCOM, INC.	-4.53%	46.41B
CENCORA, INC.	+12.75%	45.43B
HOYA CORPORATION	+7.38%	43.26B
METTLER-TOLEDO INTERNATIONAL, INC.	+19.33%	30.05B
TERUMO CORPORATION	+16.10%	25.19B
ZIMMER BIOMET HOLDINGS, INC.	-7.37%	23.34B

Other Medical Equipment, Supplies & Distribution